The antibody response against HIV-1

Cold Spring Harbor Perspectives in Medicine

Volumn 2, Issue 1, 2012, Pages

  Overbaugh, Julie ^a   Morris, Lynn ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYTOKINE; EPITOPE; GLYCAN; GLYCOPROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; IMMUNOGLOBULIN A; IMMUNOGLOBULIN F (AB) FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; NONNEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY AFFINITY; ANTIBODY COMBINING SITE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; ANTIGENIC VARIATION; ARTICLE; B LYMPHOCYTE; BROADLY CROSS NEUTRALIZING RESPONSE; CD4 LYMPHOCYTE COUNT; CELL DEATH; CRYSTAL STRUCTURE; DISEASE COURSE; DISEASE TRANSMISSION; EFFECTOR CELL; ESCAPE BEHAVIOR; GENE; GENE INTERACTION; GENE MUTATION; GERMLINE GENE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE B; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE C; HUMORAL IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOGENETICS; NONHUMAN; VIREMIA; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION; ANTIBODY PRODUCTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; REVIEW;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1;

AIDS VACCINES; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODY FORMATION; DISEASE PROGRESSION; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS;

EID: 84860153884     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a007039     Document Type: Article

References (150)

1. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S, CavaciniLA, Posner MR, Katinger H, Stiegler G, et al. 2000. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 6: 200-206.
2. Bailey JR, Lassen KG, Yang HC, Quinn TC, Ray SC, Blankson JN, Siliciano RF. 2006. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J Virol 80: 4758-4770.
3. Banks ND, Kinsey N, Clements J, Hildreth JE. 2002. Sustained antibody-dependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS. AIDS Res Hum Retrov 18: 1197-1205.
4. Barin F, Jourdain G, Brunet S, Ngo-Giang-Huong N, Weerawatgoompa S, Karnchanamayul W, Ariyadej S, Hansudewechakul R, Achalapong J, YuthavisuthiP, et al. 2006. Revisiting the role of neutralizing antibodies in mother-to-child transmission of HIV-1. J Infect Dis 193: 1504-1511.
5. Barker E, Mackewicz CE, Reyes-Teran G, Sato A, Stranford SA, Fujimura SH, Christopherson C, Chang SY, Levy JA. 1998. Virological and immunological features of long-term human immunodeficiency virus-infected individuals who have remained asymptomatic compared with those who have progressed to acquired immunodeficiency syndrome. Blood 92: 3105-3114.
6. Beirnaert E, Nyambi P, Willems B, Heyndrickx L, Colebunders R, Janssens W, van der Groen G. 2000. Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates. J Med Virol 62: 14-24.
7. Berke G. 1995. Unlocking the secrets of CTL and NK cells. Immunol Today 16: 343-346.
8. Binley J. 2009. Specificities of broadly neutralizing anti-HIV-1 sera. Curr Opin HIV AIDS 4: 364-372.
9. Binley JM, Lybarger EA, Crooks ET, Seaman MS, Gray E, Davis KL, Decker JM, Wycuff D, Harris L, Hawkins N, et al. 2008. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 82: 11651-11668.
10. Blish CA, Dogan OC, Derby NR, Nguyen MA, Chohan B, Richardson BA, Overbaugh J. 2008. HIV-1 superinfection occurs despite relatively robust neutralizing antibody responses. J Virol 82: 12094-12103.
11. Blish CA, Jalalian-Lechak Z, Rainwater S, Nguyen MA, Dogan OC, Overbaugh J. 2009. Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D HIV-1 envelope variants. J Virol 83: 7783-7788.
12. Bonsignori M, Hwang K. 2010. Immunoregulation of HIV-1 broadly neutralizing antibody responses: Deciphering maturation paths for antibody induction. In AIDS Vaccine 2010, p. A-153. Atlanta, Georgia.
13. Bosch KA, Rainwater S, Jaoko W, Overbaugh J. 2010. Temporal analysis of HIV envelope sequence evolution and antibody escape in a subtype A-infected individual with a broad neutralizing antibody response. Virology 398: 115-124.
14. Brouwer KC, Lal RB, Mirel LB, Yang C, van Eijk AM, Ayisi J, Otieno J, Nahlen BL, Steketee R, Lal AA, et al. 2004. Polymorphism of Fc receptor IIa for IgG in infants is associated with susceptibility to perinatal HIV-1 infection. Aids 18: 1187-1194.
15. Brown BK, Wieczorek L, Sanders-Buell E, Rosa Borges A, Robb ML, Birx DL, Michael NL, McCutchan FE, Polonis VR. 2008. Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. Virology 375: 529-538.
16. Bunnik EM, Pisas L, van Nuenen AC, Schuitemaker H. 2008. Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J Virol 82: 7932-7941.
17. Bures R, Morris L, Williamson C, Ramjee G, Deers M, Fiscus SA, Abdool-KarimS, Montefiori DC. 2002. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J Virol 76: 2233-2244.
18. Burns DP, Desrosiers RC. 1991. Selection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys. J Virol 65: 1843-1854.
19. Burton DR, Stanfield RL, Wilson IA. 2005. Antibody vs. HIV in a clash of evolutionary titans. Proc Natl Acad Sci 102: 14943-14948.
20. Cao Y, Qin L, Zhang L, Safrit J, Ho DD. 1995. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection [see comments]. N Engl J Med 332: 201-208.
21. + T-cell counts and T-cell function in long-term AIDS-free infection. AIDS 12: 1591-1600.
22. Cecilia D, Kleeberger C, Munoz A, Giorgi JV, Zolla-Pazner S. 1999. A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects. J Infect Dis 179: 1365-1374.
23. Chackerian B, Rudensey L, Overbaugh J. 1997. Specific N-linked and O-linked glycosylation additions in the envelope V1 domain of SIV variants that evolve in the host alter neutralizing antibody recognition. J Virol 71: 7719-7727.
24. Chohan B, Lang D, Sagar M, Korber B, Lavreys L, Richardson B, Overbaugh J. 2005. Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J Virol 79: 6528-6531.
25. Chohan BH, Piantadosi A, Overbaugh J. 2010. HIV-1 Superinfection and its implications for vaccine design. Curr HIV Res 8: 596-601.
26. Conley AJ, Kessler J-A II., Boots LJ, McKenna PM, Schleif WA, Emini EA, MarkG-E III., Katinger H, Cobb EK, Lunceford SM, et al. 1996. The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate. J Virol 70: 6751-6758.
27. Connick E, Marr DG, Zhang XQ, Clark SJ, Saag MS, Schooley RT, Curiel TJ. 1996. HIV-specific cellular and humoral immune responses in primary HIV infection. AIDS Res Hum Retrov 12: 1129-1140.
28. Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F, Fernandez-RodriguezBM, Silacci C, Pinna D, Jarrossay D, Balla-Jhagjhoorsingh S, et al. 2010. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 5: e8805.
29. Deeks SG, Schweighardt B, Wrin T, Galovich J, Hoh R, Sinclair E, Hunt P, McCune JM, Martin JN, Petropoulos CJ, et al. 2006. Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: Evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses. J Virol 80: 6155-6164.
30. Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, Denham SA, Heil ML, Kasolo F, Musonda R, Hahn BH, et al. 2004. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303: 2019-2022.
31. Dhillon AK, Donners H, Pantophlet R, Johnson WE, Decker JM, Shaw GM, LeeFH, Richman DD, Doms RW, Vanham G, et al. 2007. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol 81: 6548-6562.
32. Dickover R, Garratty E, Yusim K, Miller C, Korber B, Bryson Y. 2006. Role of maternal autologous neutralizing antibody in selective perinatal transmission of human immunodeficiency virus type 1 escape variants. J Virol 80: 6525-6533.
33. Doria-Rose NA, Klein RM, Manion MM, O'Dell S, Phogat A, Chakrabarti B, Hallahan CW, Migueles SA, Wrammert J, Ahmed R, et al. 2009. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol 83: 188-199.
34. Dreja H, O'Sullivan E, Pade C, Greene KM, Gao H, Aubin K, Hand J, Isaksen A, D'Souza C, Leber W, et al. 2010. Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: Clade C infection results in a stronger and broader humoral immune response than clade B infection. J Gen Virol 91: 2794-2803.
35. Emini EA, Schleif WA, Nunberg JH, Conley AJ, Eda Y, Tokiyoshi S, Putney SD, Matsushita S, Cobb KE, Jett CM, et al. 1992. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355: 728-730.
36. Euler Z, van Gils MJ, Bunnik EM, Phung P, Schweighardt B, Wrin T, Schuitemaker H. 2010. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J Infect Dis 201: 1045-1053.
37. Fauci AS, Johnston MI, Dieffenbach CW, Burton DR, Hammer SM, Hoxie JA, Martin M, Overbaugh J, Watkins DI, Mahmoud A, et al. 2008. HIV vaccine research: The way forward. Science 321: 530-532.
38. Florese RH, Demberg T, Xiao P, Kuller L, Larsen K, Summers LE, Venzon D, Cafaro A, Ensoli B, Robert-Guroff M. 2009. Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J Immunol 182: 3718-3727.
39. Forthal DN, Landucci G, Daar ES. 2001a. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol 75: 6953-6961.
40. + lymphocyte count. AIDS Res Hum Retrov 17: 553-561.
41. Forthal DN, Gilbert PB, Landucci G, Phan T. 2007a. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol 178: 6596-6603.
42. Forthal DN, Landucci G, Bream J, Jacobson LP, Phan TB, Montoya B. 2007b. FcγRIIa genotype predicts progression of HIV infection. J Immunol 179: 7916-7923.
43. Frost SD, Wrin T, Smith DM, Kosakovsky Pond SL, Liu Y, Paxinos E, Chappey C, Galovich J, Beauchaine J, Petropoulos CJ, et al. 2005. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci 102: 18514-18519.
44. Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M, Heyward WL, Jobes DV, Popovic V, Self SG, et al. 2005. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 191: 666-677.
45. Gnanakaran S, Lang D, Daniels M, Bhattacharya T, Derdeyn CA, Korber B. 2007. Clade-specific differences between human immunodeficiency virus type 1 clades B and C: Diversity and correlations in C3-V4 regions of gp120. J Virol 81: 4886-4891.
46. Gomez-Roman VR, Patterson LJ, Venzon D, Liewehr D, Aldrich K, Florese R, Robert-Guroff M. 2005. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol 174: 2185-2189.
47. Gorny MK, Wang XH, Williams C, Volsky B, Revesz K, Witover B, Burda S, Urbanski M, Nyambi P, Krachmarov C, et al. 2009. Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1. Mol Immunol 46: 917-926.
48. Gray ES, Moore PL, Choge IA, Decker JM, Bibollet-Ruche F, Li H, Leseka N, Treurnicht F, Mlisana K, Shaw GM, et al. 2007. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol 81: 6187-6196.
49. Gray ES, Madiga MC, Moore PL, Mlisana K, Abdool Karim SS, Binley JM, ShawGM, Mascola JR, Morris L. 2009a. Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. J Virol 83: 11265-11274.
50. Gray ES, Taylor N, Wycuff D, Moore PL, Tomaras GD, Wibmer CK, Puren A, DeCamp A, Gilbert PB, Wood B, et al. 2009b. Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J Virol 83: 8925-8937.
51. + T cell decline and high viral load during acute infection. J Virol 85: 4828-4840.
52. Harrer T, Harrer E, Kalams SA, Elbeik T, Staprans SI, Feinberg MB, Cao Y, HoDD, Yilma T, Caliendo AM, et al. 1996. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res Hum Retrov 12: 585-592.
53. Hasselrot K, Saberg P, Hirbod T, Soderlund J, Ehnlund M, Bratt G, Sandstrom E, Broliden K. 2009. Oral HIV-exposure elicits mucosal HIV-neutralizing antibodies in uninfected men who have sex with men. AIDS 23: 329-333.
54. Hengel RL, Kennedy MS, Steketee RW, Thea DM, Abrams EJ, Lambert G, McDougal JS. 1998. Neutralizing antibody and perinatal transmission of human immunodeficiency virus type 1. New York City Perinatal HIV Transmission Collaborative Study Group. AIDS Res Hum Retrov 14: 475-481.
55. Herrera C, Spenlehauer C, Fung MS, Burton DR, Beddows S, Moore JP. 2003. Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site. J Virol 77: 1084-1091.
56. Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, Lanigan CM, Landucci G, Forthal DN, Parren PW, et al. 2007. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449: 101-104.
57. Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, Bleeker WK, Parren PW, Marx PA, Burton DR. 2009. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 15: 951-954.
58. Hidajat R, Xiao P, Zhou Q, Venzon D, Summers LE, Kalyanaraman VS, Montefiori DC, Robert-Guroff M. 2009. Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J Virol 83: 791-801.
59. Hirbod T, Kaul R, Reichard C, Kimani J, Ngugi E, Bwayo JJ, Nagelkerke N, Hasselrot K, Li B, Moses S, et al. 2008. HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers. AIDS 22: 727-735.
60. Honnen WJ, Krachmarov C, Kayman SC, Gorny MK, Zolla-Pazner S, Pinter A. 2007. Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence. J Virol 81: 1424-1432.
61. Huang CC, Tang M. 2005. Structure of a V3-containing HIV-1 gp120 core. Science 310: 1025-1028.
62. Huang CC, Venturi M, Majeed S, Moore MJ, Phogat S, Zhang MY, Dimitrov DS, Hendrickson WA, Robinson J, Sodroski J, et al. 2004. Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc Natl Acad Sci 101: 2706-2711.
63. Huang KH, Bonsall D, Katzourakis A, Thomson EC, Fidler SJ, Main J, Muir D, Weber JN, Frater AJ, Phillips RE, et al. 2010. B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection. Nat Commun 1: 102.
64. Huber M, Fischer M, Misselwitz B, Manrique A, Kuster H, Niederost B, Weber R, von Wyl V, Gunthard HF, Trkola A. 2006. Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection. PLoS Med 3: e441.
65. Husson RN, Lan Y, Kojima E, Venzon D, Mitsuya H, McIntosh K. 1995. Vertical transmission of human immunodeficiency virus type 1: Autologous neutralizing antibody, virus load, and virus phenotype. J Pediatr 126: 865-871.
66. Johnson PR, Hamm TE, Goldstein S, Kitov S, Hirsch VM. 1991. The genetic fate of molecularly cloned simian immunodeficiency virus in experimentally infected macaques. Virology 185: 217-228.
67. Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, HengartnerH, Golstein P. 1994. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265: 528-530.
68. Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, WyattRT. 2008. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 6: 143-155.
69. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, SunC, Grayson T, Wang S, Li H, et al. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci 105: 7552-7557.
70. Kirchherr JL, Hamilton J, Lu X, Gnanakaran S, Muldoon M, Daniels M, KasongoW, Chalwe V, Mulenga C, Mwananyanda L, et al. 2011. Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120. Virology 409: 163-174.
71. Kliks SC, Wara DW, Landers DV, Levy JA. 1994. Features of HIV-1 that could influence maternal-child transmission. JAMA 272: 467-474.
72. Kwong PD, Wilson IA. 2009. HIV-1 and influenza antibodies: Seeing antigens in new ways. Nat Immunol 10: 573-578.
73. Kwong PD, Mascola JR, Nabel GJ. 2011. Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. Cold Spring Harb Perspect Med doi: 10. 1101/cshperspect. a007278.
74. Laird ME, Igarashi T, Martin MA, Desrosiers RC. 2008. Importance of the V1/V2 loop region of simian-human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response. J Virol 82: 11054-11065.
75. Lambotte O, Ferrari G, Moog C, Yates NL, Liao HX, Parks RJ, Hicks CB, Owzar K, Tomaras GD, Montefiori DC, et al. 2009. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 23: 897-906.
76. Legrand E, Pellegrin I, Neau D, Pellegrin JL, Ragnaud JM, Dupon M, GuillemainB, Fleury HJ. 1997. Course of specific T lymphocyte cytotoxicity, plasma and cellular viral loads, and neutralizing antibody titers in 17 recently seroconverted HIV type 1-infected patients. AIDS Res Hum Retrov 13: 1383-1394.
77. Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, Robinson JE, Decker JM, Li Y, Salazar MG, Polonis VR, et al. 2006. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol 80: 11776-11790.
78. Li Y, Svehla K, Louder MK, Wycuff D, Phogat S, Tang M, Migueles SA, Wu X, Phogat A, Shaw GM, et al. 2009. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol 83: 1045-1059.
79. Lifson JD, Haigwood NL. 2011. Lessons in nonhuman primate models for AIDS vaccine research: From minefields to milestones. Cold Spring Harb Perspect Med doi: 10. 1101/cshperspect. a007310.
80. Long EM, Martin HL Jr., Kreiss JK, Rainwater SM, Lavreys L, Jackson DJ, RakwarJ, Mandaliya K, Overbaugh J. 2000. Gender differences in HIV-1 diversity at time of infection. Nat Med 6: 71-75.
81. Loomis-Price LD, Cox JH, Mascola JR, VanCott TC, Michael NL, Fouts TR, Redfield RR, Robb ML, Wahren B, Sheppard HW, et al. 1998. Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection. J Infect Dis 178: 1306-1316.
82. Lynch JN, Nduati R, Blish C, Richardson BA, Mabuka J, Lechak Z, John-StewartGC, Overbaugh J. 2011. The breadth and potency of passively acquired HIV-specific neutralizing antibodies does not correlate with risk of infant HIV infection. J Virol 85: 5252-5261.
83. Mahalanabis M, Jayaraman P, Miura T, Pereyra F, Chester EM, Richardson B, Walker B, Haigwood NL. 2009. Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers. J Virol 83: 662-672.
84. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, Louder MK, Brown CR, Sapan CV, Frankel SS, et al. 1999. Protection of macaques against pathogenic simian/human immunodeficiency virus 89. 6PD by passive transfer of neutralizing antibodies. J Virol 73: 4009-4018.
85. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, Beary H, Hayes D, Frankel SS, Birx DL, et al. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6: 207-210.
86. Mc Cann CM, Song RJ, Ruprecht RM. 2005. Antibodies: Can they protect against HIV infection? Curr Drug Targets Infect Disord 5: 95-111.
87. McNearney T, Hornickova Z, Markham R, Birdwell A, Arens M, Saah A, Ratner L. 1992. Relationship of human immunodeficiency virus type 1 sequence heterogeneity to stage of disease. Proc Natl Acad Sci 89: 10247-10251.
88. Miller CJ, Genesca M, Abel K, Montefiori D, Forthal D, Bost K, Li J, Favre D, McCune JM. 2007. Antiviral antibodies are necessary for control of simian immunodeficiency virus replication. J Virol 81: 5024-5035.
89. Moir S, Fauci AS. 2009. B cells in HIV infection and disease. Nat Rev Immunol 9: 235-245.
90. Montefiori DC, Pantaleo G, Fink LM, Zhou JT, Zhou JY, Bilska M, Miralles GD, Fauci AS. 1996. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis 173: 60-67.
91. Moog C, Fleury HJA, Pellegrin I, Kirn A, Aubertin AM. 1997. Autologous and heterlogous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J Virol 71: 3734-3741.
92. Moore JP, Cao Y, Ho DD, Koup RA. 1994. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J Virol 68: 5142-5155.
93. Moore JP, Cao Y, Leu J, Qin L, Korber B, Ho DD. 1996. Inter-and intraclade neutralization of human immunodeficiency virus type 1: Genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol 70: 427-444.
94. Moore PL, Gray ES, Morris L. 2009a. Specificity of the autologous neutralizing antibody response. Curr Opin HIV AIDS 4: 358-363.
95. Moore PL, Ranchobe N, Lambson BE, Gray ES, Cave E, Abrahams MR, BandaweG, Mlisana K, Abdool Karim SS, Williamson C, et al. 2009b. Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog 5: e1000598.
96. O'Connell RJ, Kim JH, Corey L, Michael NL. 2011. Human immunodeficiency virus vaccine trials. Cold Spring Harb Perspect Med doi: 10. 1101/cshperspect. a007351.
97. Overbaugh J, Rudensey LM. 1992. Alterations in potential sites for glycosylation predominate during evolution of the simian immunodeficiency virus envelope gene in macaques. J Virol 66: 5937-5948.
98. Overbaugh J, Rudensey LM, Papenhausen MD, Benveniste RE, Morton WR. 1991. Variation in simian immunodeficiency virus env is confined to V1 and V4 during progression to simian AIDS. J Virol 65: 7025-7031.
99. Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, Cheng-Mayer C, MooreJP, Burton DR. 2001. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 75: 8340-8347.
100. Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, Baker B, TrochaA, Rosenberg R, Mackey E, et al. 2008. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 197: 563-571.
101. Piantadosi A, Panteleeff D, Blish CA, Baeten JM, Jaoko W, McClelland RS, Overbaugh J. 2009. HIV-1 neutralizing antibody breadth is affected by factors early in infection, but does not influence disease progression. J Virol 83: 10269-10274.
102. Pilgrim AK, Pantaleo G, Cohen OJ, Fink LM, Zhou JY, Zhou JT, Bolognesi DP, Fauci AS, Montefiori DC. 1997. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis 176: 924-932.
103. Pinter A, Honnen WJ, He Y, Gorny MK, Zolla-Pazner S, Kayman SC. 2004. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J Virol 78: 5205-5215.
104. Poss M, Martin HL, Kreiss JK, Granville L, Chohan B, Nyange P, Mandaliya K, Overbaugh J. 1995. Diversity in virus populations from genital secretions and peripheral blood from women recently infected with human immunodeficiency virus type 1. J Virol 69: 8118-8122.
105. Prince AM, Reesink H, Pascual D, Horowitz B, Hewlett I, Murthy KK, Cobb KE, Eichberg JW. 1991. Prevention of HIV infection by passive immunization with HIV immunoglobulin. AIDS Res Hum Retrov 7: 971-973.
106. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, et al. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. New Engl J Med 361: 2209-2220.
107. Richman DD, Wrin T, Little SJ, Petropoulos CJ. 2003. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci 100: 4144-4149.
108. Rodriguez SK, Sarr AD, MacNeil A, Thakore-Meloni S, Gueye-Ndiaye A, TraoreI, Dia MC, Mboup S, Kanki PJ. 2007. Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)-and HIV-2-infected Senegalese patients: Distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections. J Virol 81: 5331-5338.
109. Rong R, Bibollet-Ruche F, Mulenga J, Allen S, Blackwell JL, Derdeyn CA. 2007. Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection. J Virol 81: 1350-1359.
110. Rong R, Li B, Lynch RM, Haaland RE, Murphy MK, Mulenga J, Allen SA, Pinter A, Shaw GM, Hunter E, et al. 2009. Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog 5: e1000594.
111. Russell JH, Ley TJ. 2002. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 20: 323-370.
112. Sabin C, Corti D, Buzon V, Seaman MS, Lutje Hulsik D, Hinz A, Vanzetta F, Agatic G, Silacci C, Mainetti L, et al. 2010. Crystal structure and size-dependent neutralization properties of HK20, a human monoclonal antibody binding to the highly conserved heptad repeat 1 of gp41. PLoS Pathog 6: e1001195.
113. Sagar M. 2010. HIV-1 transmission biology: Selection and characteristics of infecting viruses. J Infect Dis 202 (Suppl 2): S289-S296.
114. Sagar M, Lavreys L, Baeten JM, Richardson BA, Mandaliya K, Ndinya-Achola JO, Kreiss JK, Overbaugh J. 2003. Identification of modifiable factors that affect the genetic diversity of the transmitted HIV-1 population. AIDS 18: 1-5.
115. Sagar M, Kirkegaard E, Long EM, Celum C, Buchbinder S, Daar ES, Overbaugh J. 2004. Human immunodeficiency virus type 1 (HIV-1) diversity at time of infection is not restricted to certain risk groups or specific HIV-1 subtypes. J Virol 78: 7279-7283.
116. Sagar M, Kirkegaard E, Lavreys L, Overbaugh J. 2006. Diversity in HIV-1 envelope V1-V3 sequences early in infection reflects sequence diversity throughout the HIV-1 genome but does not predict the extent of sequence diversity during chronic infection. AIDS Res Hum Retrov 22: 430-437.
117. Samleerat T, Thenin S, Jourdain G, Ngo-Giang-Huong N, Moreau A, Leechanachai P, Ithisuknanth J, Pagdi K, Wannarit P, Sangsawang S, et al. 2009. Maternal neutralizing antibodies against a CRF01_AE primary isolate are associated with a low rate of intrapartum HIV-1 transmission. Virology 387: 388-394.
118. Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G, Caldwell Z, Yu X, Wood B, Self S, Kalams S, et al. 2009. Factors associated with the development of cross-reactive neutralizing antibodies during Human Immunodeficiency Virus Type 1 infection. J Virol 83: 757-769.
119. Scarlatti G, Albert J, Rossi P, Hodara V, Biraghi P, Muggiasca L, Fenyo EM. 1993a. Mother-to-child transmission of human immunodeficiency virus type 1: Correlation with neutralizing antibodies against primary isolates. J Infect Dis 168: 207-210.
120. Scarlatti G, Leitner T, Hodara V, Halapi E, Rossi P, Albert J, Fenyo EM. 1993b. Neutralizing antibodies and viral characteristics in mother-to-child transmission of HIV-1. Aids 7 (Suppl 2): S45-S48.
121. Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, Ott RG, Anthony RM, Zebroski H, Hurley A, et al. 2009. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458: 636-640.
122. Schmitz JE, Kuroda MJ, Santra S, Simon MA, Lifton MA, Lin W, Khunkhun R, Piatak M, Lifson JD, Grosschupff G, et al. 2003. Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus. J Virol 77: 2165-2173.
123. Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A, Coffey RT, Harris L, Wood B, Daniels MG, et al. 2010. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 84: 1439-1452.
124. Shaw GM, Hunter E. 2011. HIV transmission. Cold Spring Harb Perspect Med doi: 10. 1101/cshperspect. a006965.
125. Shen R, Drelichman ER, Bimczok D, Ochsenbauer C, Kappes JC, Cannon JA, Tudor D, Bomsel M, Smythies LE, Smith PD. 2010. GP41-specific antibody blocks cell-free HIV type 1 transcytosis through human rectal mucosa and model colonic epithelium. J Immunol 184: 3648-3655.
126. Shibata R, Igarashi T, Haigwood N, Buckler-White A, Ogert R, Ross W, Willey R, Cho MW, Martin MA. 1999. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 5: 204-210.
127. Simek MD, Rida W, Priddy FH, Pung P, Carrow E, Laufer DS, Lehrman JK, BoazM, Tarragona-Fiol T, Miiro G, et al. 2009. Human immunodeficiency virus type 1 elite neutralizers: Individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 83: 7337-7348.
128. Smith DM, Strain MC, Frost SDW, Pillai SK, Wong JK, Wrin T, Petropolous CJ, Daar ES, Little SJ, Richman DD. 2006. Lack of nuetralizaing antibody response to HIV-1 prediposes to superinfection. Virology 355: 1-5.
129. Stamatatos L, Morris L, Burton DR, Mascola JR. 2009. Neutralizing antibodies generated during natural HIV-1 infection: Good news for an HIV-1 vaccine? Nat Med 15: 866-870.
130. Tang H, Robinson JE, Gnanakaran S, Li M, Rosenberg ES, Perez LG, Haynes BF, Liao HX, Labranche CC, Korber BT, et al. 2011. Epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals. J Virol 85: 9286-9299.
131. Tomaras G, Binley J. 2010. Epitope specificities of elite neutralizing sera from HIV-1-infected individuals. In Abstracts from AIDS Vaccine 2010, p. A-24. Atlanta, Georgia.
132. Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, Chavez LL, Decamp AC, ParksRJ, Ashley VC, Lucas JT, et al. 2008. Initial B-cell responses to transmitted human immunodeficiency virus type 1: Virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 82: 12449-12463.
133. Toran JL, Kremer L, Sanchez-Pulido L, de Alboran IM, del Real G, Llorente M, Valencia A, de Mon MA, Martinez AC. 1999. Molecular analysis of HIV-1 gp120 antibody response using isotype IgM and IgG phage display libraries from a long-term non-progressor HIV-1-infected individual. Eur J Immunol 29: 2666-2675.
134. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, SrinivasanK, Sodroski J, Moore JP, Katinger H. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 70: 1100-1108.
135. Trkola A, Kuster H, Rusert P, von Wyl V, Leemann C, Weber R, Stiegler G, Katinger H, Joos B, Gunthard HF. 2008. In vivo efficacy of human immunodeficiency virus neutralizing antibodies: Estimates for protective titers. J Virol 82: 1591-1599.
136. Walker LM, Chan-Hui P. 2010. High through-put functional screening of activated B cells from 4 African elite neutralizers yields a panel of novel broadly neutralizing antibodies. In Abstracts from AIDS Vaccine 2010, pp. A-149-A-150. Atlanta, Georgia.
137. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, et al. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285-289.
138. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, et al. 2003. Antibody neutralization and escape by HIV-1. Nature 422: 307-312.
139. Wolinsky SM, Wike CM, Korber BT, Hutto C, Parks WP, Rosenblum LL, Kunstman KJ, Furtado MR, Munoz JL. 1992. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science 255: 1134-1137.
140. Wu X, Wang C. 2010. Characterization of HIV-1 envelope variants from slow progressors who developed broadly neutralizing CD4-binding site antibodies against HIV-1. In Abstracts from AIDS Vaccine 2010, p. A-53. Atlanta, Georgia.
141. Wu X, Parast AB, Richardson BA, Nduati R, John-Stewart G, Mbori-Ngacha D, Rainwater SM, Overbaugh J. 2006. Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J Virol 80: 835-844.
142. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, SchmidtSD, Wu L, Xu L, et al. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329: 856-861.
143. Xiao X, Chen W, Feng Y, Zhu Z, Prabakaran P, Wang Y, Zhang MY, Longo NS, Dimitrov DS. 2009. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun 390: 404-409.
144. Xiao P, Zhao J, Patterson LJ, Brocca-Cofano E, Venzon D, Kozlowski PA, HidajatR, Demberg T, Robert-Guroff M. 2010. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89. 6P challenge in rhesus macaques. J Virol 84: 7161-7173.
145. Zhang LQ, MacKenzie P, Cleland A, Holmes EC, Brown AJ, Simmonds P. 1993. Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. J Virol 67: 3345-3356.
146. Zhang YJ, Fracasso C, Fiore JR, Bjorndal A, Angarano G, Gringeri A, Fenyo EM. 1997. Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors. J Infect Dis 176: 1180-1187.
147. Zhang H, Rola M, West JT, Tully DC, Kubis P, He J, Kankasa C, Wood C. 2010. Functional properties of the HIV-1 subtype C envelope glycoprotein associated with mother-to-child transmission. Virology 400: 164-174.
148. Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, Xiang SH, Yang X, Zhang MY, Zwick MB, Arthos J, et al. 2007. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445: 732-737.
149. Zhu Z, Qin HR. 2010. New broadly neutralizing human monoclonal antibodies targeting the 2F5 epitope. In Abstracts from AIDS Vaccine 2010, pp. A-14-A-15. Atlanta, Georgia.
150. Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, Ho DD. 1993. Genotypic and phenotypic characterization of HIV-1 in patients with primary infection. Science 261: 1179-1181.